Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

Documenti analoghi

• Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
  di: Ana Jiménez-Ubieto, et al.
  Pubblicazione: (2023-06-01)
• Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
  di: Ana Jiménez-Ubieto, et al.
  Pubblicazione: (2024-01-01)
• PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
  di: Noemí Álvarez Sánchez-Redondo, et al.
  Pubblicazione: (2023-08-01)
• Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
  di: Noemí Álvarez, et al.
  Pubblicazione: (2024-06-01)
• P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
  di: Irene Zamanillo, et al.
  Pubblicazione: (2023-08-01)